[Long term survival in metastatic @entity14 treated with @entity4181 and XXXX chemotherapy].

@entity1 @entity901 @entity4181 @entity2600 @entity14 @entity1487
PURPOSE: Median survival in advanced @entity14 @entity1 treated with @entity1487 (5FU) and @entity4181 (LV) is between 12 and 18 months. The aim of this study was to evaluate long term survival in this disease. METHODS: We report here, retrospectively, the survival of 445 @entity1 who entered in first-line prospective studies with LV-5FU-based regimen chemotherapy, between 1985 and 1995. RESULTS: Median survival was 18 months. The 3, 5 and 10 year survival were respectively 17.9%, 4.5% and 2.4%. Seventy-five @entity1 survived more than 3 years, among them, 10 achieved a complete and 34 a partial response, 12 had curative liver or lung surgery. Fifteen @entity1 lived more than 5 years, 2 achieved a complete and 7 a partial response. Seven had curative surgery. Eleven @entity1 were still alive in 2002, among them 7 in complete remission at 5 years, including 3 who did not have surgery. CONCLUSION: This study shows that some @entity1 with metastatic @entity14 can achieve long survival, especially when secondary curative surgery can be performed. However, 1% of the @entity1 can be cured with LV-5FU chemotherapy alone. These results will be probably improve with the use of the new drugs: @entity901 and @entity2600 .
